International Ophthalmology

, Volume 39, Issue 2, pp 431–440 | Cite as

Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration

  • Alexandros Rouvas
  • Irini ChatziralliEmail author
  • Angeliki Androu
  • Panagiota Mpougatsou
  • Dimitrios Alonistiotis
  • Maria Douvali
  • Stamatina A. Kabanarou
  • Panagiotis Theodossiadis
Original Paper



To compare the efficacy and safety of two intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents, ranibizumab and aflibercept, for the treatment of vascularized pigment epithelium detachment (vPED) due to age-related macular degeneration (AMD) in a follow-up time of 12 months.


Participants in this study were 71 patients (71 eyes) with vPED due to AMD, who were treated with intravitreal 0.5 mg ranibizumab (n = 38) or 2.0 mg aflibercept (n = 33) and had at least 12-month follow-up. All patients underwent best-corrected visual acuity (BCVA) measurement and optical coherence tomography at baseline and at every visit. The PED height, the presence of subretinal fluid (SRF), intraretinal fluid and diffuse macular edema (DME) were recorded at each visit.


There was a statistically significant difference in BCVA between the two groups at month 12 in favor of aflibercept. However, both agents were found to improve or stabilize BCVA in the majority of patients at the end of the follow-up. The change in PED height did not differ significantly between the two groups at the end of the follow-up with similar number of injections. At month 12, there was a significant improvement in SRF presence in both groups compared to baseline.


Although aflibercept was found to be superior to ranibizumab regarding BCVA improvement, both agents showed anatomical effectiveness with significant reduction in PED height and SRF absorption in patients with vPED due to AMD.


Aflibercept Age-related macular degeneration Pigment epithelium detachment Ranibizumab Treatment 


Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest and no financial disclosure.


  1. 1.
    Congdon N, O’Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P, Eye Diseases Prevalence Research Group (2004) Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122:477–485CrossRefGoogle Scholar
  2. 2.
    Joachim N, Mitchell P, Burlutsky G, Kifley A, Wang JJ (2015) The incidence and progression of age-related macular degeneration over 15 years: the Blue Mountains Eye Study. Ophthalmology 122:2482–2489CrossRefGoogle Scholar
  3. 3.
    Zając-Pytrus HM, Pilecka A, Turno-Kręcicka A, Adamiec-Mroczek J, Misiuk-Hojło M (2015) The dry form of age-related macular degeneration (AMD): the current concepts of pathogenesis and prospects for treatment. Adv Clin Exp Med 24:1099–1104CrossRefGoogle Scholar
  4. 4.
    Mehta S (2015) Age-related macular degeneration. Prim Care 42:377–391CrossRefGoogle Scholar
  5. 5.
    Holz FG, Pauleikhoff D, Klein R, Bird AC (2004) Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol 137:504–510CrossRefGoogle Scholar
  6. 6.
    Mrejen S, Sarraf D, Mukkamala SK, Freund KB (2013) Multimodal imaging of pigment epithelial detachment: a guide to evaluation. Retina 33:1735–1762CrossRefGoogle Scholar
  7. 7.
    Yannuzzi LA, Hope-Ross M, Slakter JS, Guyer DR, Sorenson JA, Ho AC, Sperber DE, Freund KB, Orlock DA (1994) Analysis of vascularized pigment epithelial detachments using indocyanine green videoangiography. Retina 14:99–113CrossRefGoogle Scholar
  8. 8.
    Pauleikhoff D, Löffert D, Spital G, Radermacher M, Dohrmann J, Lommatzsch A, Bird AC (2002) Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol 240:533–538CrossRefGoogle Scholar
  9. 9.
    Doguizi S, Ozdek S (2014) Pigment epithelial tears associated with anti-VEGF therapy: incidence, long-term visual outcome, and relationship with pigment epithelial detachment in age-related macular degeneration. Retina 34:1156–1162CrossRefGoogle Scholar
  10. 10.
    Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431CrossRefGoogle Scholar
  11. 11.
    Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57–65CrossRefGoogle Scholar
  12. 12.
    Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS (2014) Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121:193–201CrossRefGoogle Scholar
  13. 13.
    Inoue M, Arakawa A, Yamane S, Kadonosono K (2013) Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy. Retina 33:990–997CrossRefGoogle Scholar
  14. 14.
    Wolf A, Rüping J, Neubauer AS, Mayer W, Ulbig M, Haritoglou C, Holz FG, Eter N, Kampik A (2013) Alterations of vascular pigment epithelium detachments associated with age-related macular degeneration during upload with intravitreal ranibizumab. Retina 33:1843–1849CrossRefGoogle Scholar
  15. 15.
    Yüksel H, Türkcü FM, Sahin A, Sahin M, Cinar Y, Cingü AK, Ari S, Caça I (2013) One year results of anti-VEGF treatment in pigment epithelial detachment secondary to macular degeneration. Arq Bras Oftalmol 76:209–211CrossRefGoogle Scholar
  16. 16.
    Chen E, Kaiser RS, Vander JF (2007) Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 27:445–450CrossRefGoogle Scholar
  17. 17.
    Ach T, Hoeh AE, Ruppenstein M, Kretz FT, Dithmar S (2010) Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Retina 30:1420–1425CrossRefGoogle Scholar
  18. 18.
    Parodi MB, Iacono P, Papayannis A, Kontadakis SD, Cascavilla M, Pierro L, Gagliardi M, Bandello F (2013) Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series. Am J Ophthalmol 155:103–108CrossRefGoogle Scholar
  19. 19.
    Broadhead GK, Hong T, Zhu M, Li H, Schlub TE, Wijeyakumar W, Chang AA (2015) Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Retina 35:975–981CrossRefGoogle Scholar
  20. 20.
    Clemens CR, Wolf A, Alten F, Milojcic C, Heiduschka P, Eter N (2017) Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study. Acta Ophthalmol. Google Scholar
  21. 21.
    Veritti D, Sarao V, Parravano M, Arias L, Varano M, Lanzetta P (2017) One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study. Eur J Ophthalmol 27:74–79CrossRefGoogle Scholar
  22. 22.
    Wasmuth S (2010) Pathogenetic concepts for pigment epithelial detachment in exudative AMD. Ophthalmologe 107:1109–1114CrossRefGoogle Scholar
  23. 23.
    Ritter M, Bolz M, Sacu S, Deák GG, Kiss C, Pruente C, Schmidt-Erfurth UM (2010) Effect of intravitreal ranibizumab in avascular pigment epithelial detachment. Eye 24:962–968CrossRefGoogle Scholar
  24. 24.
    Iordanous Y, Powell AM, Mao A, Hooper PL, Eng KT, Schwartz C, Kertes PJ, Sheidow TG (2014) Intravitreal ranibizumab for the treatment of fibrovascular pigment epithelial detachment in age-related macular degeneration. Can J Ophthalmol 49:367–376CrossRefGoogle Scholar
  25. 25.
    Stewart MW (2012) Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol 6:1175–1186CrossRefGoogle Scholar
  26. 26.
    Chan CK, Abraham P, Meyer CH, Kokame GT, Kaiser PK, Rauser ME, Gross JG, Nuthi AS, Lin SG, Daher NS (2010) Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina 30:203–211CrossRefGoogle Scholar
  27. 27.
    Chuang EL, Bird AC (1988) The pathogenesis of tears of the retinal pigment epithelium. Am J Ophthalmol 105:285–290CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  • Alexandros Rouvas
    • 1
  • Irini Chatziralli
    • 1
    Email author
  • Angeliki Androu
    • 1
  • Panagiota Mpougatsou
    • 1
  • Dimitrios Alonistiotis
    • 1
  • Maria Douvali
    • 1
  • Stamatina A. Kabanarou
    • 2
  • Panagiotis Theodossiadis
    • 1
  1. 1.2nd Department of Ophthalmology, Attikon HospitalUniversity of AthensAthensGreece
  2. 2.Medical Retina Department, Korgialeneio BenakeioRed Cross HospitalAthensGreece

Personalised recommendations